Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
Open Access
- 1 January 2013
- journal article
- review article
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2013, 1-9
Abstract
Background. Many studies have found that the antibiotic rifaximin is effective for the treatment of hepatic encephalopathy. However, there is no uniform view on the efficacy and safety of rifaximin.Methods. We performed a meta-analysis through electronic searches to evaluate the efficacy and safety of rifaximin in comparison with nonabsorbable disaccharides.Results. A total of 8 randomized controlled trials including 407 patients were included. The efficacy of rifaximin was equivalent to nonabsorbable disaccharides according to the statistical data (risk ratio (RR): 1.06, 95% CI: 0.94–1.19;). Analysis showed that patients treated with rifaximin had better results in serum ammonia levels (weighted mean difference (WMD): −10.63, 95% CI: −30.63–9.38;), mental status (WMD: −0.32, 95% CI: −0.67–0.03;), asterixis (WMD: −0.12, 95% CI: −0.31–0.08;), electroencephalogram response (WMD: −0.21, 95% CI: −0.34–−0.09;), and grades of portosystemic encephalopathy (WMD: −2.30, 95% CI: −2.78–−1.82;), but only the last ones had statistical significance. The safety of rifaximin was better than nonabsorbable disaccharides (RR: 0.19, 95% CI: 0.10–0.34;).Conclusion. Rifaximin is at least as effective as nonabsorbable disaccharides, maybe better for the treatment of hepatic encephalopathy. And the safety of rifaximin is better.
Keywords
Funding Information
- National Natural Science Foundation of China (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
- National Natural Science Foundation of China (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
- National Natural Science Foundation of China (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
- National Natural Science Foundation of China (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
- Shanghai Science and Technology Foundation (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
- Chinese Foundation for Hepatitis Prevention and Control the WBN Research Foundation (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
- Shanghai Municipal Health Bureau Foundation (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
- Shanghai Municipal Health Bureau Foundation (81270515, 81101579, 81072005, 81172312, 11430702400, 20100021, 2011287, 2012107)
This publication has 33 references indexed in Scilit:
- A Current Review of the Diagnostic and Treatment Strategies of Hepatic EncephalopathyInternational Journal of Hepatology, 2012
- Durability of Rifaximin Response in Hepatic EncephalopathyJournal of Clinical Gastroenterology, 2012
- Hepatic encephalopathySaudi Journal of Gastroenterology, 2012
- Assessment of low-grade hepatic encephalopathy: A critical analysisJournal of Hepatology, 2007
- Hepatic Encephalopathy As a Predictor of Survival in Patients with End-Stage Liver DiseaseLiver Transplantation, 2007
- Review article: the current pharmacological therapies for hepatic encephalopathyAlimentary Pharmacology & Therapeutics, 2007
- Management of Hepatic Encephalopathy: Role of RifaximinChemotherapy, 2005
- Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trialJournal of Hepatology, 2003
- Hepatic encephalopathyAmerican Journal of Gastroenterology, 2001
- Liver disease, aminoglycoside antibiotics and renal dysfunctionHepatology, 1988